CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 478 enrolled
Drug / intervention
Amlodipine +1 moredrug
Likely dose
Amlodipine 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00700271
NCT00700271Phase 4Completed
CompareCT.gov

Efficacy of a Combination of Amlodipine / Valsartan on Blood Pressure Control, With One Nocturnal or Diurnal Intake a Day, in Ambulatory Blood Pressure Monitoring Setting, in Essential Uncontrolled Hypertensive Patients With Amlodipine 5mg ; The ExPERT Study

Novartis Pharmaceuticals·interventional·Posted Jun 18, 2008·Updated May 19, 2011

In Brief

A Phase 4 clinical trial evaluating Amlodipine and Valsartan for Hypertension. Completed, enrolled 478 participants across 2 sites in 2 countries.

Detailed Summary

This study was a multicenter, randomized, PROBE-type (prospective, randomized, open label, blinded end-point) study of 12 weeks duration comprising four visits, carried out in patients with essential arterial hypertension not controlled on four weeks treatment with amlodipine 5 mg alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesFrance, Tunisia
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 18, 2008
Enrollment StartOct 1, 2007
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 18.0 years ago

Interventions

Amlodipinedrug

5 mg or 10 mg tablets.

Valsartandrug

160 mg capsules.